Intrepid Family Office’s Spero Therapeutics SPRO Stock Holding History

Intrepid Family Office’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,279	Closed	-$38.1K	–	42
2026 Q1	$38.1K	Sell	16,279 -148,721	-90%	-$353K	0.03%	38
2025 Q4	$384K	Buy	165,000 +55,000	+50%	+$128K	0.33%	32
2025 Q3	$207K	Buy	+110,000	New	+$242K	0.17%	33

Other funds holding SPRO

GSK plc London $602M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Intrepid Family Office's SPRO Position: Q2 2026 in Review

Intrepid Family Office sold out of Spero Therapeutics (SPRO) in Q2 2026, closing a stake of 16,279 shares — an estimated $38.1K sold.

Intrepid Family Office first reported a position in SPRO in Q3 2025 and held it in 3 quarters. The position peaked at $384K in Q4 2025. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

Intrepid Family Office reported no remaining Spero Therapeutics position as of Q2 2026 after selling out during the quarter.
Intrepid Family Office sold 16,279 Spero Therapeutics shares in Q2 2026, an estimated $38.1K.
Intrepid Family Office first reported a position in Spero Therapeutics in Q3 2025 and held it in 3 quarters.
Intrepid Family Office's Spero Therapeutics position peaked at $384K in Q4 2025.
60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Intrepid Family Office's 13F filing for Q2 2026, filed 14 Aug 2026.